Table 1 Demographic characteristics of study population
From: Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study
|  | Respondents (n = 123) |
|---|---|
Sex | |
 Male | 23 (18.7%) |
 Female | 99 (80.5%) |
 Non-Binary | 1 (0.8%) |
Age | |
 18–24 | 7 (5.7%) |
 25–34 | 24 (19.5%) |
 35–44 | 35 (28.4%) |
 45–54 | 23 (18.7%) |
 55–64 | 24 (19.5%) |
 65–74 | 6 (4.9%) |
 75+ | 4 (3.3%) |
 Mean | 44.9 |
 Median | 41.0 |
 Range | 18.0–83.0 |
 SD | 14.4 |
Province | |
 Atlantic Canada | 10 (8.1%) |
 Ontario | 33 (26.8%) |
 Quebec | 23 (18.7%) |
 Western Canada | 57 (46.3%) |
HAE Type | |
 HAE-1 | 56 (45.5%) |
 HAE-2 | 17 (13.8%) |
 HAE nC1-INH | 30 (24.4%) |
 Unsure | 20 (16.3%) |
Treatment Type | |
 Prophylaxis + On-demand | 105 (85.3%) |
 On demand only | 18 (14.6%) |
HAE Treatment Medication– Routine Prophylaxis (n = 105) | |
 Intravenous pdC1inh | 32 (30.5%) |
 Danazol | 1 (0.9%) |
 Subcutaneous pdC1inh | 51 (48.6%) |
 Lanadelumab | 14 (13.3%) |
 Tranexamic Acid | 1 (0.9%) |
 Other | 6 (5.7%) |
HAE Treatment Medication– On-Demand (n = 120) | |
 Intravenous pdC1inh | 75 (61.0%) |
 Icatibant | 28 (22.8%) |
 Icatibant + intravenous pdC1NH | 3 (2.4%) |
 Subcutaneous pdC1inh | 13 (10.6%) |
 Other | 1 (0.8%) |
Age of HAE Symptoms Onset | |
 1–17 | 84 (68.3%) |
 18–24 | 15 (12.2%) |
 25–34 | 7 (5.7%) |
 35–44 | 6 (4.9%) |
 45–54 | 6 (4.9%) |
 55–64 | 4 (3.3%) |
 65–74 | 1 (0.8%) |
 75+ | 0 (0.0%) |
 Mean | 17.6 |
 Median | 13.0 |
 SD | 15.0 |
Age of HAE Diagnosis | |
 1–17 | 31 (25.2%) |
 18–24 | 22 (17.9%) |
 25–34 | 27 (22.0%) |
 35–44 | 18 (14.6%) |
 45–54 | 11 (8.9%) |
 55–64 | 9 (7.3%) |
 65–74 | 3 (2.4%) |
 75+ | 2 (1.6%) |
 Mean | 29.7 |
 Median | 26.0 |
 SD | 17.6 |
Age of HAE Treatment Initiation | |
 1–17 | 18 (14.6%) |
 18–24 | 26 (21.1%) |
 25–34 | 29 (23.6%) |
 35–44 | 22 (17.9%) |
 45–54 | 14 (11.4%) |
 55–64 | 9 (7.3%) |
 65–74 | 2 (1.6%) |
 75+ | 3 (2.4%) |
 Mean | 32.4 |
 Median | 29.0 |
 SD | 16.2 |